Muromonab-CD3

In the US, Muromonab-CD3 (muromonab-cd3 systemic) is a member of the drug class selective immunosuppressants and is used to treat Rejection Prophylaxis and Rejection Reversal.

US matches:

• Muromonab-CD3


• Muromonab-cd3 Intravenous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AA02

CAS registry number (Chemical Abstracts Service)

0140608-64-6

Therapeutic Category

Selective immunosuppressant

Chemical Name

A biochemically purified IgG2α immunoglobulin consisting of a heavy chain of approx. 50.000 daltons and a light chain of approx. 25.000 daltons.

Foreign Names

• Muromonabum-CD3 (Latin)
• Muromonab-CD3 (German)
• Muromonab-CD3 (French)
• Muromonab-CD3 (Spanish)

Generic Names

• Muromonab-CD3 (OS: DCF, JAN, USAN)
• Anti-CD3 (IS)
• Human T-cell inhibitor (IS)

Brand Names

• Okt
  Santa-Farma, Turkey



• OKT3
  Janssen, Venezuela



• Orthoclone OKT3
  Janssen, Luxembourg; Janssen, Mexico; Janssen, Netherlands; Janssen, New Zealand; Janssen-Cilag, France; Ortho Biotech, United States; Santa-Farma, Turkey



• Orthoclone
  Janssen, Australia; Janssen, Belgium; Janssen, Costa Rica; Janssen, Germany; Janssen, Dominican Republic; Janssen, Finland; Janssen, Greece; Janssen, Guatemala; Janssen, Honduras; Janssen, Israel; Janssen, Italy; Janssen, Nicaragua; Janssen, Panama; Janssen, El Salvador; Janssen Pharmaceutical K.K., Japan

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.